We have a drug that analyst are saying Analyst Andrew Vaino writes that “safety appears remarkable”
We have a drug thai is the first to phase 3
Synta’s drug is poised to be the first second generation HSP-90 inhibitor to make it to a Phase 3 clinical study, Mr. Vaino said.
This is IMO just the start. We either have those that are trying on purpose to bring the stock down, or they just dont have a clue. We even have mention of looking for partner's which should not be hard.
We have been encouraged by the partnership interest in these and other, earlier-stage programs at the company and are confident we will conclude one or more partnership agreements this year. We anticipate partnerships contributing substantial resources and complementary activities to our programs.”